Ultragenyx Wins FDA Nod for First Sanfilippo Syndrome Gene Therapy
- The FDA granted full approval on September 17, 2026 to FAYUVI (rebisufligene etisparvovec-hopf, also known as UX111), an AAV-based gene therapy developed by Ultragenyx.
- FAYUVI is indicated for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), or Sanfilippo syndrome Type A — a progressive, fatal neurodegenerative disorder sometimes called "childhood Alzheimer's" that causes developmental delay followed by loss of cognitive, language, and motor function.
- It is the first-ever FDA-approved treatment for Sanfilippo syndrome Type A and represents Ultragenyx's second approved gene therapy overall.
- The approval qualified Ultragenyx for a Priority Review Voucher.
- Commercial product is expected to begin shipping to Qualified Treatment Centers within 30 to 60 days.
Second AAV gene therapy approval in Ultragenyx's stable is the real headline here — it validates a repeatable regulatory and manufacturing playbook for ultra-rare CNS disease, not a one-off. That de-risks the rest of the pipeline (other MPS subtypes, Angelman, etc.) in investors' eyes far more than the Sanfilippo indication itself. The Priority Review Voucher is worth watching separately: PRVs have changed hands for $100M+ in recent years, so this is a monetizable balance-sheet asset Ultragenyx can sell or redeem, not just a regulatory footnote. On revenue, ultra-rare gene therapies typically carry seven-figure list prices against a tiny diagnosed population — expect a slow, lumpy ramp gated by Qualified Treatment Center onboarding and payer negotiations rather than the 30-60 day shipping window. No approved or late-stage competitor targets MPS IIIA specifically, so Ultragenyx effectively owns this niche outright — for now.
FDA approves a new gene therapy for Sanfilippo syndrome, an ultra-rare disease ↗